2025-12-12 sec-litreleases complaint 272 KB 140 chars

SEC v. RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.; and DONAL R. SCHMIDT, JR., No. 3:23-cv-02081, Northern District of Texas (Dec. 12, 2025) — Complaint

raw: SEC v. RAPID THERAPEUTIC SCIENCE

SEC v. RAPID THERAPEUTIC SCIENCE, No. 3:23-cv-02081 (Dec. 12, 2025)

Caption
Securities and Exchange Commission v. Rapid Therapeutic Science Laboratories Inc
Exhibit of Rapid Therapeutic Science Laboratories, Inc. and Donal R. Schmidt, Jr.
Source PDF JSON

Enriched metadata

Scheme
unregistered-securities (95%)
Court
Northern District of Texas
Case No.
3:23-cv-02081
Victim loss
$1,150,000
Entity
Rapid Therapeutic Science Laboratories, Inc.
Ticker
RTSL
CIK
0001575659
Classified unregistered-securities(confidence 95%). EDGAR detection: forms Form D/S-1· recall 41% / precision 30%. detection rule →
Statutes
15 U.S.C. § 77v15 U.S.C. § 78aa15 U.S.C. § 78j(b)15 U.S.C. § 77q(a)15 U.S.C. § 78m(a)15 U.S.C. § 77t(g)15 U.S.C. § 78u(d)15 U.S.C. § 77t(e)15 U.S.C. § 78l15 U.S.C. § 78o(d)15 U.S.C. § 77t(d)17 C.F.R. § 240.10b-517 C.F.R. § 240.13a-14Sections 20(b), 20(d), and 22 of the Securities ActSections 20(b), 20(d), and 22 of the Securities ActSections 20(b), 20(d), and 22 of the Securities ActSections 21(d), 21(e), and 27 of the Securities Exchange ActSections 21(d), 21(e), and 27 of the Securities Exchange ActSections 21(d), 21(e), and 27 of the Securities Exchange ActSection 17(a) of the Securities ActSections 5(a) and 5(c) of the Securities ActSections 5(a) and 5(c) of the Securities ActSection 20(g) of the Securities ActSection 20(e) of the Securities ActRule 10b-5Rule 13a-14
Parties
Securities and Exchange CommissionRapid Therapeutic Science Laboratories IncDonal R Schmidt, JrADR Provider
Keywords
rapidschmidtexchangerapid schmidtsecsecuritiesdocument pagepage pageidsecurities exchangeexchange exchangecv-companydocumentpagepageid

Extracted insights

Entities 3
  • company Rapid Therapeutic Science Laboratories, Inc. ×2
  • person Donal R. Schmidt, Jr.
  • agency Securities and Exchange Commission
Triples 11
  • Securities And Exchange Commission files this Complaint against Rapid Therapeutic Science Laboratories, Inc. and Donal R. Schmidt, Jr.
  • Donal R. Schmidt, Jr. drafted, disseminated, and/or filed press releases, investor communications, SEC filings, and website posts containing materially false and misleading claims
  • Rapid Therapeutic Science Laboratories, Inc. raised at least $2.1 million from 51 investors in 15 states in unregistered securities transactions
  • Donal R. Schmidt, Jr. sold Rapid stock that he personally owned, receiving approximately $1.15 million
  • Rapid Therapeutic Science Laboratories, Inc. is registered with the Commission under Exchange Act Section 12(g)
  • Rapid Therapeutic Science Laboratories, Inc. files periodic reports with the SEC
  • Rapid Therapeutic Science Laboratories, Inc. trades under the ticker symbol Rtsl on OTC Link
  • Donal R. Schmidt, Jr. is Rapid’s CEO, president, and board chairman
  • Donal R. Schmidt, Jr. is a licensed attorney and CPA in Texas
  • Donal R. Schmidt, Jr. used a private entity that he controlled to acquire a majority interest in an SEC-reporting company
  • Donal R. Schmidt, Jr. changed the company’s name and its business operations to form Rapid
PDF
SEC v. RAPID THERAPEUTIC SCIENCE · Source
Text layers
Extracted body text (140c) 
[OCR_UNRECOVERABLE method=recover reason=missing_pdf ts=2026-09-26T14:05:04.885Z]